References
-
1
Baptista T, Kin N M, Beaulieu S, de Baptista E A.
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanism, management and research perspectives.
Pharmacopsychiatry.
2002;
35
205-219
-
2
Cohen D.
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Pharmacopsychiatry.
2004;
37
1-11
-
3 FDA-alert. Injury Lawyer-Warning about ZYPREXA (olanzapine). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id = 222
-
4
Folstein M F, Folstein S E, McHugh P R.
”Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res.
1975;
12
189-198
-
5 Fujisawa Pharmaceutical Co., Ltd. ‘Dear Doctor’ Letter, Japan, 7 November, 2002 (in Japanese).
-
6
Howard A A, Amsten J H, Gourevitch M N.
Effect of alcohol consumption on diabetes mellitus.
Ann Intern Med.
2004;
140
211-219
-
7
Jin H, Meyer J M, Jeste D V.
Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: and analysis of 45 published cases.
Ann Clin Psychiatry.
2002;
14
59-64
-
8
Koller E A, Weber J, Doraiswamy P M, Schneider B S.
A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.
J Clin Psychiatry.
2004;
65
857-863
-
9
Meyer J M, Leckband S G, Loh C C, Moutier C Y.
Quetiapine-induced diabetes with metabolic acidosis.
Int Clin Psychopharmacol.
2004;
19
169-171
-
10
Wilson D R, D’Souza L, Sarkar N, Newton M, Hammond C.
New-onset diabetes and ketoacidosis with atypical antipsychotics.
Schizophr Res.
2003;
59
1-6
Megumi Takahashi, M.D., Ph. D.
Department of Psychiatry
Kitasato University School of Medicine
2-1-1 Asamizodai
Sagamihara 228-8520
Japan
Telefon: +81 42 748 9111
Fax: +81 42 765 3570
eMail: megumita@kitasato-u.ac.jp
